

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: Analyses from the pan-European TOCERRA register collaboration

DOI:

[10.1136/annrheumdis-2017-212845](https://doi.org/10.1136/annrheumdis-2017-212845)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Lauper, K., Nordström, D. C., Pavelka, K., Hernández, M. V., Kvien, T. K., Kristianslund, E. K., Santos, M. J., Rotar, Z., Iannone, F., Codreanu, C., Lukina, G., Gale, S. L., Sarsour, K., Luder, Y., Courvoisier, D. S., & Gabay, C. (2018). Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: Analyses from the pan-European TOCERRA register collaboration. *Annals of the rheumatic diseases*, 77(9), 1276-1282. <https://doi.org/10.1136/annrheumdis-2017-212845>

Published in:

Annals of the rheumatic diseases

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.



Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

